<DOC>
	<DOCNO>NCT02698618</DOCNO>
	<brief_summary>The purpose study determine whether Ticagrelor protective effect microcirculation percutaneous coronary intervention patient Diabetes mellitus type II pre-diabetic status .</brief_summary>
	<brief_title>PRotective Effect Coronary Microcirculation Patients With DIabetes Clopidogrel Ticagrelor</brief_title>
	<detailed_description>Introduction : Patients Diabetes Mellitus ( DM ) Type 2 still consistently perform bad non-diabetic counterpart especially set Percutaneous Coronary Intervention ( PCI ) . The abnormal coronary microcirculation along high risk distal embolization particle release PCI target lesion constitute main cause peri-procedural microcirculatory damage . New antiplatelet agent , particular Ticagrelor , might also play protective role microcirculation . Ticagrelor inhibit cellular uptake adenosine , increase circulating level adenosine inhibition physiological clearance . Adenosine may protect myocardium ischemic , reperfusion injury via potent vasodilatory effect possibly anti-inflammatory antiplatelet property . Additionally previous research identify profound effect adenosine microcirculatory resistance associate obesity diabetes high myocardial protective effect Ticagrelor PCI might expect high risk subgroup patient . The purpose PRotective Effect Coronary Microcirculation Patients With DIabetes Clopidogrel Ticagrelor ( PREDICT ) trial design investigate protective effect Ticagrelor microcirculation PCI stable diabetic patient Rationale : 1 . Coronary plaque high risk distal embolization PCI , like one thin-cap fibroatheroma ( TCFA ) , prevalent patient DM . Thus , population high risk develop myocardial injury microcirculation impairment subsequent PCI . 2 . By block Adenosine transporter ( ENT ) 1 nucleoside cell membrane transporter , Ticagrelor inhibit cellular uptake adenosine , increase circulating level adenosine inhibition physiological clearance . Adenosine may protect myocardium ischemic , reperfusion injury via potent vasodilatory effect possibly anti-inflammatory antiplatelet property . This translate adenosine-mediated vasodilatory effect ticagrelor take place soon load dose . 3 . Previous research group identify profound effect adenosine microcirculatory resistance associate obesity diabetes high myocardial protective effect Ticagrelor PCI might expect high risk subgroup patient . ( enhanced microcirculatory response raise adenosine level ) . Giving premise diabetic pre-diabetics patient , Ticagrelor treatment pre-PCI might improve microcirculatory parameter ( low resistance ) compare clopidogrel ( secondary hypothesis ) . Ticagrelor might superior clopidogrel provide microcirculatory protection PCI procedure subgroup patient ( primary hypothesis ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Subject Diabetes Mellitus ( DM ) Type II Subject must older 18 year Written inform consent available Subject stable ischemic heart disease refer coronary angiography Subject eligible PCI , PCI target ( ) FFR≤0.80 Prior myocardial infarction territory target vessel Akinesia dyskinesia subtend myocardial segment Severe impairment leave ventricular function ( LVEF ) &lt; 35 % PCI target chronic total occlusion Target lesion treat previously ( restenotic lesion ) Target vessel saphenous vein graft surgical graft anastomose target vessel Thrombolisis Myocardial Infarction ( TIMI ) flow ≤ 1 prior guide wire cross Subject eligible treatment DES Bleeding disorder chronic anticoagulant treatment Left main stenosis &gt; 50 % Coronary surgery deem beneficial patient PCI Intolerance contraindication antiplatelet drug Contraindications adenosine administration Platelet count &lt; 75000 &gt; 700000/mm3 Immunosuppressive therapy Pregnant breast feed patient History intracranial haemorrhage Severe hepatic impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>IMR</keyword>
	<keyword>Microcirculation</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>CFR</keyword>
	<keyword>FFR</keyword>
	<keyword>Coronary microcirculation</keyword>
</DOC>